Member LoginDividend CushionValue Trap | 
            
               
  Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for
  any changes.
 
    Latest
    Valuentum Commentary
   
Sep 5, 2018
     
        
      There Is Milk At The Store 
  "Now this is not the end. It is not even the beginning of the end. But it is, perhaps, the end of the beginning." -- Winston Churchill Aug 6, 2018
     
        
      Valuentum’s Weighted Average Cost of Capital (WACC) Distribution 
  The weighted average cost of capital is one of the most subjective measures in corporate finance, but it is also one of the most important ones. May 30, 2018
     
        
      Study: Valuentum's Best Ideas Newsletter Portfolio 
  "Though we largely achieved the Best Ideas Newsletter portfolio’s goals in advancing the newsletter portfolio each publication year (ends December 15) and achieving relative outperformance and risk-adjusted superiority to the benchmark, we may have done even better had our equity allocation been full during the measurement period." -- Brian Nelson, CFA May 18, 2018
     
        
      Dividend Increases/Decreases for the Week Ending May 18 
  Let's take a look at companies that raised/lowered their dividend this week. May 10, 2018
     
        
      Generic Drug Deflation Continues to Hamper Cardinal Health and AmerisourceBergen 
  Image Source: Aaron Fulkerson. A severe case of rampant generic drug deflation continues to hamper the share prices of Cardinal Health and AmerisourceBergen. We are monitoring the drug deflation numbers posted by the drug wholesalers as a key gauge of the investment merits of the group. Apr 18, 2018
     
        
      ICYMI: Valuentum’s Improved Stock and ETF Web Pages 
  Valuentum has rolled out improved stock and ETF web pages on its website www.valuentum.com. Now, subscribers can access key proprietary information on the stock and ETF web pages in addition to the customary stock and ETF reports. Mar 12, 2018
     
        
      The "Luck" and "Randomness" of Index Funds 
  If the year-to-year performance of active funds relative to index funds can be considered “random,” so then is the year-to-year performance of index funds relative to active funds, regardless of fees and expenses. Image shown: page 1 of 14. Feb 16, 2018
     
        
      Dividend Increases/Decreases for the Week Ending February 16 
  Let's take a look at companies that raised/lowered their dividend this week. Dec 19, 2017
     
        
      Video: Quants! You're NOT Measuring VALUE and Nelson's Theory of Universal Value 
  President of Investment Research Brian Nelson defines the concept of universal value and shows how quantitative statistical methods are inextricably linked to those of fundamental, financial, business-model related analysis. Value does not exist in respective process vacuums! Value is universal. Find out why. Running time: ~10 minutes. Latest News and Media The High Yield Dividend Newsletter, Best Ideas
    Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on
    this website are for information purposes only and should not be considered a solicitation to buy or sell any
    security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s
    accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or
    omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts
    no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a
    registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees,
    and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site. 
                   | 
                      
Image Source: Global Panorama. Healthcare product distributor and Dividend Aristocrat Cardinal Health has had its share price performance in 2018 dampened by a number of factors, including generic drug price deflation weighing on its ‘Pharmaceutical’ segment, struggles in its ‘Medical’ segment, and the potential for disruption within its industry.